Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.

Antimicrobial Agents and Chemotherapy
D J FarrellD Felmingham

Abstract

Sixteen (1.5%) of the 1,043 clinical macrolide-resistant Streptococcus pneumoniae isolates collected and analyzed in the 1999-2000 PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) study have resistance mechanisms other than rRNA methylation or efflux. We have determined the macrolide resistance mechanisms in all 16 isolates by sequencing the L4 and L22 riboprotein genes, plus relevant segments of the four genes for 23S rRNA, and the expression of mutant rRNAs was analyzed by primer extension. Isolates from Canada (n = 4), Japan (n = 3), and Australia (n = 1) were found to have an A2059G mutation in all four 23S rRNA alleles. The Japanese isolates additionally had a G95D mutation in riboprotein L22; all of these originated from the same collection center and were clonal. Three of the Canadian isolates were also clonal; the rest were not genetically related. Four German isolates had A2059G in one, two, and three 23S rRNA alleles and A2058G in two 23S rRNA alleles, respectively. An isolate from the United States had C2611G in three 23S rRNA alleles, one isolate from Poland had A2058G in three 23S rRNA alleles, one isolate from Turkey had A2058G in four 23S rRNA alleles, and one isol...Continue Reading

References

Jan 1, 1988·Methods in Enzymology·C D SigmundE A Morgan
Jun 11, 1984·Nucleic Acids Research·C D SigmundE A Morgan
Mar 1, 1995·Antimicrobial Agents and Chemotherapy·B Weisblum
Nov 1, 1996·Antimicrobial Agents and Chemotherapy·J SutcliffeL Wondrack
Dec 3, 1999·Antimicrobial Agents and Chemotherapy·M C RobertsH Seppala
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·B Vester, S Douthwaite
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·G A SyrogiannopoulosT A Davies
Jun 13, 2001·Molecular Microbiology·J Usary, W S Champney
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·Marja PihlajamäkiJari Jalava
Mar 15, 2002·Cell·Tanel Tenson, Måns Ehrenberg
Mar 15, 2002·Cell·Hitoshi Nakatogawa, Koreaki Ito
Jun 19, 2002·Antimicrobial Agents and Chemotherapy·Brigitte MalbrunyRoland Leclercq
Aug 2, 2002·Molecular Cell·Jeffrey L HansenThomas A Steitz
Dec 5, 2002·Current Drug Targets. Infectious Disorders·Jacob Poehlsgaard, Stephen Douthwaite

❮ Previous
Next ❯

Citations

Jan 22, 2004·Current Infectious Disease Reports·John R. Lonks
Jan 17, 2004·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Jack B AnonUNKNOWN Sinus And Allergy Health Partnership
Dec 13, 2006·Nature Reviews. Drug Discovery·Lynn L Silver
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jay C ButlerFred C Tenover
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul H Edelstein
Oct 16, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nancy F CrumKevin L Russell
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John R Lonks, Donald A Goldmann
Sep 24, 2004·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·C E NordR Leclercq
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Silpak BiswasJean-Marc Rolain
Nov 26, 2009·Antimicrobial Agents and Chemotherapy·Agnes WongD Ashley Robinson
Nov 26, 2010·Antimicrobial Agents and Chemotherapy·Vanessa G AllenRoberto G Melano
Jan 11, 2007·Antimicrobial Agents and Chemotherapy·Nicole WolterKeith P Klugman
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Guy W NovotnyStephen Douthwaite
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·James H JorgensenCynthia G Whitney
Apr 24, 2004·Antimicrobial Agents and Chemotherapy·David J Farrell, David Felmingham
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Nicole WolterKeith P Klugman
Apr 28, 2006·Antimicrobial Agents and Chemotherapy·Scott E GygaxMartin E Adelson
Nov 8, 2005·Journal of Clinical Microbiology·Diego FacconeAlejandra Corso
Nov 5, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aymen YassinAlexander S Mankin
Mar 30, 2005·Proceedings of the National Academy of Sciences of the United States of America·Peter PfisterErik C Böttger
Jul 22, 2009·Research in Microbiology·Jelena BegovicLjubisa Topisirovic
Dec 17, 2008·Journal of Molecular Biology·Alexandros D PetropoulosDimitrios L Kalpaxis
Mar 15, 2008·International Journal of Antimicrobial Agents·Nicole WolterUNKNOWN Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa
Jan 8, 2008·International Journal of Antimicrobial Agents·David J FarrellWaleria Hryniewicz
Apr 7, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N Woodford
Nov 23, 2006·The Medical Clinics of North America·Gary V Doern
Oct 1, 2005·Molecular Microbiology·Stephen DouthwaiteLene Jakobsen
Dec 24, 2011·Annals of the New York Academy of Sciences·Krishna Kannan, Alexander S Mankin
Apr 22, 2006·Diagnostic Microbiology and Infectious Disease·Linda P DiPersioLinda A DeFine
Sep 8, 2005·International Journal of Antimicrobial Agents·Prachi K DandekarDavid P Nicolau
Jun 5, 2004·Clinics in Laboratory Medicine·Bülent Bozdogan, Peter C Appelbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.